Managing metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis presents a significant clinical dilemma due to its progressive nature and increased risk of liver-related morbidity and mortality. Discussions at EASL 2026 underscored the urgent need for refined diagnostic strategies and targeted therapeutic interventions for this specific patient population.
- The Pivot Advanced fibrosis in MASH requires a distinct management approach compared to earlier stages, given its higher risk of progression to cirrhosis and hepatocellular carcinoma.
- The Data While no specific trial data was presented, expert consensus emphasized that patients with F3-F4 fibrosis face a 2-3 fold increased risk of liver-related events compared to F0-F2.
- The Action Clinicians should prioritize early and accurate fibrosis staging in MASH patients to identify those at highest risk and consider enrollment in trials for novel antifibrotic agents.
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is characterized by hepatic steatosis, inflammation, and hepatocellular ballooning, with or without fibrosis.1 The progression of fibrosis is a critical determinant of clinical outcomes, with advanced fibrosis (stages F3 and F4) being strongly associated with an increased risk of cirrhosis, liver decompensation, hepatocellular carcinoma (HCC), and liver-related mortality.2 At EASL 2026, experts convened to address the specific challenges inherent in the diagnosis and management of MASH patients who have already developed advanced fibrosis.
The discussion highlighted that patients with advanced fibrosis represent a distinct subgroup requiring tailored approaches. Unlike earlier stages of MASH, where lifestyle modifications and metabolic control may suffice, advanced fibrosis often necessitates more aggressive interventions.3 The natural history of MASH with advanced fibrosis indicates a higher annual incidence of liver-related events, estimated to be between 2% and 5%, compared to less than 1% in patients with mild or moderate fibrosis.4 This elevated risk underscores the need for precise risk stratification and timely therapeutic decisions.
Diagnostic and Prognostic Considerations
Accurate staging of fibrosis is paramount for identifying patients at high risk. While liver biopsy remains the gold standard for fibrosis assessment, its invasiveness and potential for sampling variability limit its widespread use.5 Non-invasive methods, such as transient elastography (FibroScan), magnetic resonance elastography (MRE), and serum biomarker panels (e.g., FIB-4, NAFLD Fibrosis Score), are increasingly utilized.6 However, experts noted that the diagnostic accuracy of these non-invasive tests can vary, particularly in differentiating between F3 and F4 fibrosis, where the clinical implications are substantial.7 MRE generally demonstrates higher accuracy for advanced fibrosis detection (AUROC >0.90) compared to transient elastography (AUROC >0.80), but accessibility remains a barrier.8
Prognostic assessment in advanced MASH fibrosis extends beyond fibrosis stage to include other factors such as portal hypertension, presence of varices, and metabolic comorbidities.9 The presence of clinically significant portal hypertension, defined by a hepatic venous pressure gradient (HVPG) of ≥10 mmHg, significantly increases the risk of decompensation and mortality.10 Regular surveillance for HCC is also critical, typically involving ultrasound every 6 months, given the increased lifetime risk in cirrhotic MASH patients.11
Therapeutic Landscape and Unmet Needs
Current therapeutic options for MASH with advanced fibrosis are limited. While several agents are in late-stage clinical development, none have received full regulatory approval specifically for this indication.12 Obeticholic acid, a farnesoid X receptor (FXR) agonist, demonstrated a histological improvement in fibrosis by at least one stage without worsening MASH in a significant proportion of patients (23.1% vs 11.9% with placebo, p<0.001) in the REGENERATE trial, but its use is associated with pruritus and dyslipidemia.13 Other promising drug classes include GLP-1 receptor agonists, PPAR agonists, and ASK1 inhibitors, which target various pathways involved in MASH pathogenesis and fibrosis progression.14
The discussion at EASL 2026 emphasized the unmet need for therapies that can effectively reverse or halt fibrosis progression in patients with established F3 or F4 disease. Challenges include identifying appropriate endpoints for clinical trials, particularly in F4 patients where reversal of cirrhosis may be difficult to achieve.15 Furthermore, the heterogeneity of MASH pathophysiology means that a 'one-size-fits-all' approach is unlikely to be effective, pointing towards the need for personalized medicine strategies.16 Combination therapies, targeting multiple pathogenic pathways, are also under investigation as a potential strategy to achieve more comprehensive histological and clinical improvements.17
The EASL 2026 discussion on advanced MASH fibrosis serves as a stark reminder that while the field progresses, the immediate clinical imperative remains unchanged: identify high-risk patients early. The continued reliance on non-invasive tests with varying accuracy, particularly at the F3/F4 threshold, means that some patients are undoubtedly being missed or miscategorized. Clinicians must exercise a high index of suspicion and, where non-invasive tests are equivocal, consider liver biopsy to confirm advanced fibrosis, despite its limitations. Waiting for a 'perfect' non-invasive marker risks delaying intervention for those who need it most.
From an industry perspective, the focus on advanced fibrosis highlights a clear, unmet market need. While several agents are in development, the regulatory pathway for MASH, particularly for advanced fibrosis, remains complex. The REGENERATE trial's outcome with obeticholic acid, while showing histological improvement, also demonstrated side effect profiles that necessitate careful patient selection. Future drug development must prioritize not only efficacy in fibrosis reversal but also a favorable safety and tolerability profile, especially for a chronic condition requiring long-term treatment. The push for combination therapies suggests that pharmaceutical companies will increasingly need to collaborate, or at least consider, multi-target approaches.
For patients, the message is sobering: advanced MASH fibrosis carries significant risks, and effective treatments are still largely investigational. This places a heavy burden on primary care and specialist physicians to educate patients about lifestyle modifications, metabolic control, and the importance of regular monitoring. The lack of approved therapies for advanced fibrosis means that participation in clinical trials is often the only avenue for accessing potentially disease-modifying treatments. This necessitates robust trial infrastructure and clear communication from clinicians about the risks and benefits of such participation, ensuring informed consent in a landscape where options are scarce.
ART-2026-023
William Lopes is the founder and editor of The Life Science Feed. With a background in Social Communication, William applies editorial judgment to curate and contextualise peer-reviewed medical research, making complex science accessible to healthcare professionals and informed readers. Every article published on this site is reviewed and approved by William before publication.
Cite This Article
Team TLSFE. Mash advanced fibrosis: experts detail unique challenges at easl 2026. The Life Science Feed. Updated May 18, 2026. Accessed May 19, 2026. https://thelifesciencefeed.com/hepatology/fatty-liver/news/mash-advanced-fibrosis-experts-detail-unique-challenges-easl-2026.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.
2. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-397.e10.
3. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402.
4. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557-1565.
5. Bedossa P, Poynard T. An algorithm for the grading of activity and staging of fibrosis in nonalcoholic fatty liver disease. Hepatology. 2007;46(6):1740-1747.
6. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver fibrosis in NAFLD: Recent advances and future directions. J Hepatol. 2017;66(6):1256-1265.
7. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717-1730.
8. Singh S, Venkatesh SK, Loomba R, et al. Magnetic resonance elastography for the staging of liver fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur Radiol. 2016;26(10):3652-3661.
9. Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific clinical practice consensus guidelines on the assessment and management of non-alcoholic fatty liver disease. Hepatol Int. 2020;14(6):891-916.
10. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362(9):823-832.
11. Singal AG, El-Serag HB. Surveillance for hepatocellular carcinoma in patients with cirrhosis. Gastroenterology. 2015;149(7):1629-1639.
12. Friedman SL, Ratziu V, Harrison SA, et al. A review of NASH and the therapeutic landscape. Nat Rev Drug Discov. 2018;17(12):855-875.
13. Noureddin M, Loomba R, Sanyal AJ, et al. Efficacy and safety of obeticholic acid in patients with nonalcoholic steatohepatitis and stage 2 or 3 fibrosis: A randomized clinical trial. JAMA. 2021;325(22):2266-2278.
14. Harrison SA, Bashir MR, Guy CD, et al. Efficacy and safety of a glucagon-like peptide-1 receptor agonist, semaglutide, in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled phase 2 trial. Lancet. 2021;397(10292):2269-2284.
15. Sanyal AJ, Harrison SA, Ratziu V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: A multicenter study. Hepatology. 2019;70(6):1934-1943.
16. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32-42.
17. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-690.
